Sign In
Buy RHHBY
$49.06
-0.130 (-0.264%)
At Close: Jun 03, 2026
FDA Approves Genentech's Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
06:30pm, Thursday, 02'nd Oct 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentr
Basel, 1 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of 89bio, Inc. (89bio) (NASDAQ: ETNB)
Labcorp Announces Collaboration with Roche to Advance Digital Pathology Capabilities
07:00am, Tuesday, 30'th Sep 2025
Labcorp to leverage Roche's digital pathology technology to expand access, enhance efficiency and support AI integration across anatomic pathology services BURLINGTON, N.C. , Sept. 30, 2025 /PRNewswir
Data show Roche's sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks
01:00am, Tuesday, 30'th Sep 2025
Basel, 30 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the primary results from the TSIX Study Program, which evaluated the performance of its new sixth-generation high-sensitivity Tr
Peanut allergy is a growing health concern, especially in children, with rising incidence and increased public awareness of its severity and risks. This
Roche points to U.S. plans after Trump pharma tariff announcement
02:42am, Friday, 26'th Sep 2025
Switzerland's Roche on Friday pointed to the fact that one of its U.S. units broke ground on a new facility in August and that the pharma company had pledged major U.S. investments after President Don
Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial
02:01am, Thursday, 25'th Sep 2025
Roche Pharmaceuticals' CEO told investors she was "serious" about the goal of becoming a top 3 obesity player. The drugmaker's CT-388 weight loss injection is entering a phase III trial, marking the l
Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025
02:30am, Wednesday, 24'th Sep 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presents new data for Ocrevus® (ocrelizumab) and the investigational Bruton's tyrosi
Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025
02:30am, Wednesday, 24'th Sep 2025
Basel, 24 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presents new data for OCREVUS® (ocrelizumab) and the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib at the 41st Co
Roche Holding AG - Special Call
07:03pm, Monday, 22'nd Sep 2025
Roche Holding AG - Special Call Company Participants Bruno Eschli - Head of Investor Relations Teresa Graham - Chief Executive Officer of Roche Pharmaceuticals Levi Garraway - Executive VP, Head of Gl
Roche Targets Top Spot In Weight Loss Drug Market
02:04pm, Monday, 22'nd Sep 2025
Roche Holdings AG RHHBY on Monday outlined its plan to become a leading player in the surging weight-loss drug market, pushing its obesity pipeline farther into late-stage development as it eyes compe
Roche CEO, pharma execs to meet with Swiss government over US tariffs
09:54am, Monday, 22'nd Sep 2025
Roche Chief Executive Thomas Schinecker and other senior executives from the Swiss pharmaceuticals industry will meet with the government on Monday to discuss the threat U.S. tariffs pose to the cruci
Roche shares rise as firm advances experimental obesity drug to late-stage trial
05:01am, Monday, 22'nd Sep 2025
Shares in Roche Holding rose around 2% on Monday, outperforming a broadly unchanged European healthcare index , as the drugmaker said it was advancing its experimental obesity drug CT-388 to a late-st
Roche's Drug Candidate Meets Main Goals in Late-Stage Breast Cancer Study
02:08am, Monday, 22'nd Sep 2025
The pharmaceutical company said that giredestrant in combination with everolimus significantly improved progression-free survival in patients with advanced breast cancer.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating investigat
